CAS |
No.1622902-68-4 |
中文名称 |
阿布罗替尼 |
英文名称 |
Abrocitinib |
别名 |
PF-04965842 |
分子式 |
C14H21N5O2S |
分子量 |
323.41 |
溶解性 |
Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
SMILES |
CN([C@H]1C[C@@H](NS(CCC)(=O)=O)C1)C2=C3C(NC=C3)=NC=N2 |
靶点 |
JAK,TYK2 |
通路 |
JAK/STAT Signaling |
背景说明 |
Abrocitinib是一种新型,有效的JAK1抑制剂。 |
生物活性 |
Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease[1]. |
In Vitro |
Abrocitinib(Compound 25)inhibits IFNα-stimulated phosphorylation of STAT3,IFN-stimulated phosphorylation of STAT1 in human whole blood(HWB),as well as pSTAT5 in CD34+ spiked into HWB(JAK2),with IC50s of 189,163 nM,7.178 μM,respectively[1]. |
In Vivo |
Abrocitinib(Compound 25; 5,15,50 mg/kg,p.o.,daily for 7 days)significantly reduces paw swelling in rat adjuvant-induced arthritis model[1]. |
数据来源文献 |
[1]. Vazquez ML, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J Med Chem. 2018 Feb 8;61(3):1130-115 |
规格 |
1mg 5mg 10mg |
单位 |
瓶 |